Da Volterra is proud to join academic and EFPIA partners in the COMBACTE-CDI consortium which was launched in November 2017.
The COMBACTE consortium announces the addition of COMBACTE-CDI as a new project. The project aims to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe. The ultimate goal is to contribute to improved treatment options for patients suffering from such infections that are responsible for extensive morbidity, mortality and health care costs.
The 3-year COMBACTE-CDI project merges European expertise on clinical, diagnostic and therapeutic issues related to C. difficile infection (CDI). It brings together experts that previously have partnered in large international CDI projects, the largest existing IMI-funded clinical and laboratory networks in Europe for execution of challenging epidemiological and interventional studies (incl. those caused by antimicrobial -resistant bacteria) and a network mapping all European surveillance activities related to antimicrobial resistance.
Please see the press release for more information.